Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection.

Pai JK, Curhan GC, Cannuscio CC, Rifai N, Ridker PM, Rimm EB.

Clin Chem. 2002 Oct;48(10):1781-4. No abstract available.

2.

[Novel biomarkers: adiponectin in contemporary diagnosis of cardiovascular diseases].

Pal'tseva EM, Konstantinova SV, Severin SE.

Kardiologiia. 2009;49(10):65-74. Review. Russian. No abstract available.

PMID:
19845523
3.

Novel antecedent plasma biomarkers of cardiovascular disease: improved evaluation methods and comparator benchmarks raise the bar.

Welsh P, Packard CJ, Sattar N.

Curr Opin Lipidol. 2008 Dec;19(6):563-71. doi: 10.1097/MOL.0b013e32831551e0. Review.

PMID:
18957878
4.

[Emerging risk factors for cardiovascular disease].

Demant T.

Dtsch Med Wochenschr. 2004 Jan 30;129(5):204-9. Review. German. No abstract available.

PMID:
14735418
5.

Controversies regarding hormone therapy: Insights from inflammation and hemostasis.

Koh KK, Yoon BK.

Cardiovasc Res. 2006 Apr 1;70(1):22-30. Epub 2006 Jan 17. Review.

6.
7.

Apo B/apo A-I ratio and cardiovascular risk prediction.

Lima LM, Carvalho Md, Sousa MO.

Arq Bras Cardiol. 2007 Jun;88(6):e187-90. Review. English, Portuguese. No abstract available.

8.

Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease?

Rubin C, Nolin TD, Himmelfarb J.

Curr Opin Nephrol Hypertens. 2007 Nov;16(6):506-11. Review.

PMID:
18089962
9.

Candidate circulating biomarkers for the cardiovascular disease continuum.

Dotsenko O, Chackathayil J, Patel JV, Gill PS, Lip GY.

Curr Pharm Des. 2008;14(24):2445-61. Review.

PMID:
18781994
10.

Coming of age of C-reactive protein: using inflammation markers in cardiology.

Yeh ET, Willerson JT.

Circulation. 2003 Jan 28;107(3):370-1. Review. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk